Next Article in Journal
Impact of the Implementation of a Bovine Viral Diarrhea Virus Targeted Vaccine in Dairy Farms: Longitudinal Analysis
Previous Article in Journal
Antigen-Dependent Adjuvanticity of Poly(lactic-co-glycolic acid)-polyethylene Glycol 25% Nanoparticles for Enhanced Vaccine Efficacy
Previous Article in Special Issue
Comparison of Post-Vaccination Response (Humoral and Cellular) to BNT162b2 in Clinical Cases, Kidney and Pancreas Transplant Recipient with Immunocompetent Subjects over Almost Two Years of Parallel Monitoring
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

COVID-19 and Transplant Patients: Challenges, Risks, and Evolving Strategies

by
Mariarosaria Campise
Department of Nephrology, Dialysis and Kidney Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
Vaccines 2025, 13(3), 318; https://doi.org/10.3390/vaccines13030318
Submission received: 5 March 2025 / Accepted: 11 March 2025 / Published: 17 March 2025
(This article belongs to the Special Issue SARS-CoV-2 Infection and Vaccines for Patients with Renal Diseases)
The first cases of COVID-19 were reported in December 2019 in Wuhan, China. The disease, caused by the SARS-CoV-2 virus, is believed to have originated from a zoonotic spillover, possibly linked to a market selling live animals in damp conditions. The exact source remains a topic of scientific debate, with theories ranging from natural transmission from bats to potential leaks from a laboratory [1,2].
Initially, local authorities in Wuhan attempted to manage the outbreak without raising international alarm. However, by late January 2020, the virus had spread beyond China’s borders, reaching countries such as Thailand, Republic of Korea, Japan, and USA, as well as European nations. The World Health Organization (WHO) declared COVID-19 a Public Health Emergency of International Concern on 30 January 2020. Just over a month later, on 11 March 2020, the WHO officially declared COVID-19 a pandemic, recognizing its rapid global spread and severe consequences [3,4].
Governments around the world responded to COVID-19 with varying degrees of urgency. Aggressive testing, contact tracing, and quarantine measures, were implemented to contain early outbreaks. However, misinformation and healthcare infrastructure limitations soon became a cause for concern. Lockdowns, travel restrictions, and social distancing measures were widely imposed. These measures, though necessary, had severe economic and social consequences. Businesses shut down, unemployment rates soared, and educational institutions moved online, disrupting millions of students’ learning experiences. The psychological impact of prolonged isolation also became evident, leading to a rise in mental health issues worldwide.
The scientific community mobilized rapidly to understand the virus and develop countermeasures.
Early treatments focused on managing symptoms and preventing severe complications.
The COVID-19 pandemic posed significant challenges to the global healthcare system, especially in vulnerable populations such as solid organ transplant (SOT) recipients. Due to their immunosuppressed status, these patients are at an increased risk for severe SARS-CoV-2 infections, leading to higher associated complications and mortality rates compared to the general population. In general, the mortality rate was higher in all SOT patients: those undergoing kidney [5,6], lung [7], liver, and combined transplants [8]. In SOT patients, the treatment of COVID-19 requires a delicate balance between controlling viral replication and maintaining adequate immunosuppression. Indeed, immunosuppression, necessary to prevent organ rejection was identified as a contributing factor to the higher susceptibility and severity of infections in this group. Furthermore, comorbidities common among SOT patients, such as diabetes, hypertension, and chronic kidney disease, further increased the risk of severe COVID-19 outcomes.
Several therapies were attempted including Chloroquine/Hydroxychloroquine, Azithromycin, lopinavir-ritonavir, Ivermectin, corticosteroids, convalescent plasma, heparin, zinc, Montelukast, and monoclonal antibody. However, these drugs including antivirals, have shown highly variable effectiveness or yielded mixed results [9].
A breakthrough in COVID-19 treatment came with the development of vaccines.
By December 2020, less than a year after the pandemic began, the first COVID-19 vaccines—Pfizer-BioNTech and Moderna—received emergency use authorization in several countries. This was a historic achievement in vaccine development. Soon after, other vaccines, including AstraZeneca, Johnson & Johnson, and Sinopharm, followed, providing hope for mass immunization and pandemic control [10,11].
However, the efficacy of vaccines in SOT recipients has been a subject of concern because immunosuppressive therapy may sensibly reduce the immune response to vaccines. Their efficacy in preventing infection and severe disease may be lower than in the general population, but the paramount advantage of vaccinations is their ability to reduce the severity of infection [12].
To enhance vaccine-induced protection, many studies have explored the administration of additional doses. Research published in the Lancet demonstrated that a third dose of an mRNA COVID-19 vaccine significantly improved the immune response in SOT recipients who had previously exhibited suboptimal responses to the standard two-dose regimen [13].
Just as vaccines began rolling out, new variants of SARS-CoV-2 emerged. The Alpha, Beta, Delta, and Omicron variants demonstrated the virus’s ability to mutate, sometimes increasing transmissibility and reducing vaccine effectiveness. These variants led to new waves of infections and hospitalizations, particularly in regions with low vaccination rates [14,15].
Misinformation and vaccine hesitancy also hindered efforts to reach herd immunity. Anti-vaccine movements, fueled by distrust in pharmaceutical companies and governments, led to resistance against vaccination campaigns, prolonging the pandemic’s impact [16].
Among other concerns, the pandemic highlighted deep social inequalities. Low-income communities and marginalized groups suffered disproportionately due to limited access to healthcare, job losses, and overcrowded living conditions that increased infection risks. Women, particularly those in caregiving roles, have been forced to leave work since schools and daycare centers closed. Furthermore, some countries could not afford the high cost of vaccines set by the manufacturers, especially low-income countries in Africa. To overcome this problem, COVID-19 Vaccines Global Access (COVAX) was created [17]. By 31 December 2023, COVAX had delivered 2 billion doses of COVID-19 vaccines to 58 lower-income economies, preventing over 2 million deaths and achieving 57% of two-doses coverage compared to the global average of 67% [18].
The delivery of vaccines will continue into 2025 in those countries that requested further doses in 2024.
On 5 May 2023, the World Health Organization officially declared the end of a pandemic that began just over three years earlier, on 11 March 2020.
The COVID-19 pandemic has been a challenge; however, it also accelerated advancements in technology and healthcare. Telemedicine became a mainstream option for medical consultations, reducing the strain on hospitals [19]. Remote work and online learning platforms saw widespread adoption, changing traditional work and education models.
Artificial intelligence played a crucial role in pandemic management, from predicting outbreaks to accelerating drug discovery. Digital health tools, such as contact tracing apps and vaccination passports, became essential in monitoring and controlling the spread of the virus [20].
Today, COVID-19 has been downgraded to the causative agent of a respiratory tract infection. However, for some patients, such as SOT recipients, it can develop into a high-risk infection if it is not early diagnosed and treated. The lessons learned from all the lives lost must not be forgotten.
Investing in pandemic preparedness, promoting scientific literacy, and fostering international cooperation are essential to ensuring better future health resources for humanity. The legacy of COVID-19 should be one of resilience, innovation, and a commitment to a healthier, more equitable world.

Conflicts of Interest

The author declares no conflicts of interest.

References

  1. Li, Q.; Guan, X.; Wu, P.; Wang, X.; Zhou, L.; Tong, Y.; Ren, R.; Leung, K.S.M.; Lau, E.H.Y.; Wong, J.Y.; et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N. Engl. J. Med. 2020, 382, 1199. [Google Scholar] [CrossRef]
  2. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497, Erratum in Lancet 2020, 395, 496. https://doi.org/10.1016/S0140-6736(20)30252-X. [Google Scholar] [CrossRef]
  3. WHO Director-General’s Opening Remarks at the Media Briefing on COVID19—March 2020. Available online: www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---27-july-2020 (accessed on 27 February 2025).
  4. World Health Organization. Coronavirus Disease 2019 (COVID-19): Situation Report—38. 27 February 2020. Available online: www.who.int/docs/default-source/coronaviruse/situation-reports/20200227-sitrep-38-covid-19 (accessed on 27 February 2025).
  5. Cancarevic, I.; Nassar, M.; Daoud, A.; Ali, H.; Nso, N.; Sanchez, A.; Parikh, A.; Ul Hosna, A.; Devanabanda, B.; Ahmed, N.; et al. Mortality rate of COVID-19 infection in end stage kidney disease patients on maintenance hemodialysis: A systematic review and meta-analysis. World J. Virol. 2022, 11, 352. [Google Scholar] [CrossRef]
  6. Campise, M.; Alfieri, C.M.; Perego, M.; Tamborini, F.; Cresseri, D.; Gandolfo, M.T.; Binda, V.; Regalia, A.; Messa, P. COVID-19 Infection in Kidney Transplant Patients: An Italian One Year Single Centre Experience. Pathogens 2021, 10, 964. [Google Scholar] [CrossRef]
  7. Messika, J.; Eloy, P.; Roux, A.; Hirschi, S.; Nieves, A.; Le Pavec, J.; Sénéchal, A.; Saint Raymond, C.; Carlier, N.; Demant, X.; et al. French Group of Lung Transplantation. COVID-19 in Lung Transplant Recipients. Transplantation 2021, 105, 177. [Google Scholar] [CrossRef]
  8. Hardgrave, H.; Wells, A.; Nigh, J.; Klutts, G.; Krinock, D.; Osborn, T.; Bhusal, S.; Rude, M.K.; Burdine, L.; Giorgakis, E. COVID-19 Mortality in Vaccinated vs. Unvaccinated Liver & Kidney Transplant Recipients: A Single-Center United States Propensity Score Matching Study on Historical Data. Vaccines 2022, 10, 1921. [Google Scholar] [CrossRef]
  9. Yuan, Y.; Jiao, B.; Qu, L.; Yang, D.; Liu, R. The development of COVID-19 treatment. Front. Immunol. 2023, 14, 1125246. [Google Scholar] [CrossRef]
  10. Prasad, V.; Haslam, A. COVID-19 vaccines: History of the pandemic’s great scientific success and flawed policy implementation. Monash Bioeth. Rev. 2024, 42, 28–54. [Google Scholar] [CrossRef]
  11. Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021, 384, 403. [Google Scholar] [CrossRef]
  12. Chen, X.; Luo, D.; Mei, B.; Du, J.; Liu, X.; Xie, H.; Liu, L.; Su, S.; Mai, G. Immunogenicity of COVID-19 vaccines in solid organ transplant recipients: A systematic review and meta-analysis. Clin. Microbiol. Infect. 2023, 29, 441–456. [Google Scholar] [CrossRef]
  13. Barda, N.; Dagan, N.; Cohen, C.; Hernán, M.A.; Lipsitch, M.; Kohane, I.S.; Reis, B.Y.; Balicer, R.D. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study. Lancet 2021, 398, 2093. [Google Scholar] [CrossRef]
  14. Collier, A.Y.; Yu, J.; McMahan, K.; Liu, J.; Chandrashekar, A.; Maron, J.S.; Atyeo, C.; Martinez, D.R.; Ansel, J.L.; Aguayo, R.; et al. Differential Kinetics of Immune Responses Elicited by COVID-19 Vaccines. N. Engl. J. Med. 2021, 385, 2010–2012. [Google Scholar] [CrossRef]
  15. Wang, Q.; Guo, Y.; Bowen, A.; Mellis, I.A.; Valdez, R.; Gherasim, C.; Gordon, A.; Liu, L.; Ho, D.D. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe 2024, 32, 315–321.e3. [Google Scholar] [CrossRef]
  16. Baghani, M.; Fathalizade, F.; Loghman, A.H.; Samieefar, N.; Ghobadinezhad, F.; Rashedi, R.; Baghsheikhi, H.; Sodeifian, F.; Rahimzadegan, M.; Akhlaghdoust, M. COVID-19 vaccine hesitancy worldwide and its associated factors: A systematic review and meta-analysis. Sci. One Health 2023, 2, 100048. [Google Scholar] [CrossRef]
  17. Gavi, the Vaccine Alliance. COVAX Explained. 2023. Available online: https://www.gavi.org/vaccineswork/covax-explained (accessed on 27 February 2025).
  18. World Health Organization. COVID-19 Vaccinations Shift to Regular Immunization as COVAX Draws to a Close. 2023. Available online: https://www.who.int/news/item/19-12-2023-covid-19-vaccinations-shift-to-regular-immunization-as-covax-draws-to-a-close (accessed on 27 February 2025).
  19. Omboni, S.; Padwal, R.S.; Alessa, T.; Benczúr, B.; Green, B.B.; Hubbard, I.; Kario, K.; Khan, N.A.; Konradi, A.; Logan, A.G.; et al. The worldwide impact of telemedicine during COVID-19: Current evidence and recommendations for the future. Connect. Health Telemed. 2022, 1, 7–35. [Google Scholar] [CrossRef]
  20. Gawande, M.S.; Zade, N.; Kumar, P.; Gundewar, S.; Weerarathna, I.N.; Verma, P. The role of artificial intelligence in pandemic responses: From epidemiological modeling to vaccine development. Mol. Biomed. 2025, 6, 1. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Campise, M. COVID-19 and Transplant Patients: Challenges, Risks, and Evolving Strategies. Vaccines 2025, 13, 318. https://doi.org/10.3390/vaccines13030318

AMA Style

Campise M. COVID-19 and Transplant Patients: Challenges, Risks, and Evolving Strategies. Vaccines. 2025; 13(3):318. https://doi.org/10.3390/vaccines13030318

Chicago/Turabian Style

Campise, Mariarosaria. 2025. "COVID-19 and Transplant Patients: Challenges, Risks, and Evolving Strategies" Vaccines 13, no. 3: 318. https://doi.org/10.3390/vaccines13030318

APA Style

Campise, M. (2025). COVID-19 and Transplant Patients: Challenges, Risks, and Evolving Strategies. Vaccines, 13(3), 318. https://doi.org/10.3390/vaccines13030318

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop